You are here

We are astonished at the current lack of attention to osteoarthritis”. Correo Farmacéutico interviews Josep Escaich

21 Oct 2011
Bioiberica

The general manager of Bioiberica highlighted his company’s commitment to a comprehensive approach to the treatment of osteoarthritis: prevention, chondroprotector drugs, and personalized medicine. Together, all these elements improve the patients’ quality of life.

Correo Farmacéutico devoted his weekly "Companies" section to Bioibérica. In an interview given to this specialized newspaper, Josep Escaich, Bioiberica´s general director, analyzed the current crisis in the pharmaceutical sector and highlighted the need of searching for new opportunities and to adapt ourselves to the new rules of play. Moreover, Escaich defended Bioiberica Farma’s comprehensive approach to osteoarthritis as the right strategy to improve the patients’ quality of life.


For further information, go to:
http://www.correofarmaceutico.com/2011/10/17/farmacologia/estamos-estupefactos-ante-el-desamparo-en-artrosis

http://www.correofarmaceutico.com/2011/10/17/farmacologia/debemos-aceptar-las-nuevas-reglas-del-juego-y-buscar-oportunidades-entre-ellas

Related News

19 Apr 2022
Bioiberica

This endorses the company's commitment and responsibility to strengthen and consolidate its ethical corporate governance based on the strictest legal and regulatory standards.

11 Apr 2022
Bioiberica

Since Bioiberica was first established, our mission has been to improve the health of people, animals and plants worldwide. Our purpose – to take care of life sustainably through science – is driven by the desire to build a better future.